Clinical trials: Pulmonary Artery Pressure
Heart Failure, Left-Sided Heart Failure
CardioMEMS HF System Post Approval Study
The purpose of the CardioMEMS HF System Post Approval Study (PAS) is to evaluate the use of the CardioMEMS HF System in patients with NYHA class III heart failure in a commercial setting.
- Conditions
- Heart Failure, Left-Sided Heart Failure, Congestive Heart Failure
- Trial name
- NCT02279888
- Testing
- CardioMEMS HF System
- Where
- United States
- Volunteers
- 1,214 people
- Sponsor
- Abbott Medical Devices
NYHA Class III Heart Failure
Bioimpedance Spectroscopy Compared to CardioMEMS™
Comparison of changes in diastolic pulmonary artery pressure as measured by CardioMEMS™ to impedance parameters as measured by ImpediMed's BIS technology.
- Trial name
- NCT02857231
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- ImpediMed Limited
Pulmonary Arterial Hypertension
A Study to Learn About the Study Medicine Called PF-07868489 in Healthy Adult People and in People With Pulmonary Arterial Hypertension
The purpose of the study is to learn how the study medicine called PF-07868489 is tolerated and acts in healthy adult people and people with pulmonary arterial hypertension (PAH).
- Trial name
- NCT06137742
- Testing
- PF-07868489
- Where
- 46 sites in United States, Australia and 10 more
- Volunteers
- 97 people, healthy volunteers welcome
- Sponsor
- Pfizer
Pulmonary Arterial Hypertension
Long-term Extension Study of the Safety and Pharmacokinetics of QCC374 in PAH Patients
This is a long-term open-label safety extension to the Phase 2a study of inhaled QCC374 in adult patients with PAH. This study provides the patients who completed the QCC374X2201 study with the option to continue receiving…
- Trial name
- NCT02939599
- Testing
- QCC374
- Where
- 4 sites in United States, Germany and 1 more
- Volunteers
- 5 people
- Sponsor
- Novartis Pharmaceuticals
Heart Failure
Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal
The purpose of this study is to evaluate and document appropriate clinical safety and performance of the Remon CHF Implantable Pressure Sensor including the corresponding delivery system, the Remon CHF Home Unit, the Remon CHF…
- Trial name
- PAPIRUSII (NCT00604903)
- Testing
- Implant of Pressure sensor.
- Volunteers
- 42 people
- Sponsor
- Boston Scientific Corporation
Pulmonary Arterial Hypertension
Measuring Blood Pressure in the Lung Circulation With Sonar Technology (Echo-Doppler)
This is a non-invasive study using a standard doppler echocardiographic transducer which records signals emanating from the lungs (TPD). These signals are caused by pulsation of blood vessels in the lung tissue.
- Trial name
- NCT01357746
- Testing
- Transthoracic pulmonary doppler recording
- Where
- Israel
- Volunteers
- 60 people
- Sponsor
- Echosense Ltd.
Heart Failure
Vivio At-Home Study
The purpose of the study is to examine the Vivio System's ability to track heart failure status in subjects, and compare the Vivio System's measurements to CardioMEMS measurements.
- Trial name
- NCT07730268
- Testing
- Vivio measurement
- Where
- 4 sites in United States
- Volunteers
- 500 people
- Sponsor
- Ventric Health, LLC
Heart Failure
Voice Analysis to Detect Pulmonary Arterial Pressure Changes in Heart Failure
VAPP-HF is a prospective, multi-center, observational study assessing whether daily voice recordings analyzed by a machine learning algorithm can detect changes in pulmonary arterial (PA) pressure in heart failure patients with…
- Trial name
- VAPP-HF (NCT07443670)
- Testing
- Daily Voice Recording
- Where
- 3 sites in United States, Germany
- Volunteers
- 60 people
- Sponsor
- Noah Labs
Hypertension, Pulmonary
Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs
Study to determine the long term safety of tadalafil in patients with increased blood pressure in the blood vessel that carries blood from the right heart to the lungs and to see if it will keep the disease from getting worse.
- Trial name
- NCT00549302
- Testing
- tadalafil
- Where
- 10 sites in United States, Belgium and 8 more
- Volunteers
- 357 people
- Sponsor
- Eli Lilly and Company
Hypertension, Pulmonary
This Study Tests the Safety of Inhaled BAY1237592, How the Drug is Tolerated and How it Effects Patients With High Blood Pressure in the Arteries of the Lungs in the Two Different Disease Groups Pulmonary Arterial Hypertension (PAH) and Chronic Thromboembolic Pulmonary Hypertension (CTEPH)
In this trial the effects of the inhaled drug BAY1237592 will be studied in patients with high blood pressure in the pulmonary blood vessels due to Pulmonary Arterial Hypertension (PAH) and due to Chronic Thromboembolic Pulmonary…
- Trial name
- ATMOS (NCT03754660)
- Testing
- BAY1237592
- Where
- 8 sites in Austria, Czechia and 2 more
- Volunteers
- 38 people
- Sponsor
- Bayer
Catheter, Newborn, Infant, Disease
Evaluation of Intravascular Monitoring of Partial PRessure of Oxygen for Neonatal intensiVE Care Patients -2
The study is a non-blinded trial with one single intervention in sick newborn infants. The Neosense umbilical catheter will be used instead of the routinely used umbilical catheter on infants where the treating physician has…
- Conditions
- Catheter, Newborn, Infant, Disease, Lung Diseases
- Trial name
- IMPROVE-2 (NCT05433779)
- Testing
- Neosense Umbilical Catheter
- Where
- 5 sites in Sweden
- Volunteers
- 8 people
- Sponsor
- Neosense Technologies
Pulmonary Fibrosis, Pulmonary Hypertension
Inhaled Iloprost in Adults With Abnormal Pulmonary Pressure and Associated With Idiopathic Pulmonary Fibrosis
The primary purpose of this study is to determine whether iloprost inhalation solution is safe in subjects with idiopathic pulmonary fibrosis (IPF) and elevated pulmonary arterial pressure.
- Trial name
- NCT00109681
- Testing
- Iloprost Inhalation Solution (Ventavis)
- Where
- 17 sites in United States
- Volunteers
- 50 people
- Sponsor
- Actelion
Pulmonary Heart Disease
A Study of Commercial DEFINITY® to Monitor the Effects of the Heart's Pulmonary Artery Pressure
The purpose of this clinical research is to learn if DEFINITY® 416 will cause any adverse effects during Right Heart Catheterization. This research was requested by the FDA.
- Trial name
- NCT00918866
- Testing
- Definity
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Lantheus Medical Imaging
Heart Failure
Monitoring Pulmonary Artery Pressure by Implantable Device Responding to Ultrasonic Signal (PAPIRUS III)
The PAPIRUS III study will continue to follow patients initially enrolled in PAPIRUS II. Pressure readings from the investigational device will continue to be collected and will be correlated to physiological changes during…
- Trial name
- PAPIRUSIII (NCT00893828)
- Where
- Germany
- Volunteers
- 18 people
- Sponsor
- Boston Scientific Corporation
Right Heart Catheterization
The Nanowear Wearable System SimpleSense Validation Trial for Cardiac Output
The Nanowear SimpleSense study is a single center, prospective, non-randomized, feasibility, non- significant risk study The study will be done in 2 phases.
- Trial name
- NCT05629533
- Testing
- SimpleSense
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Nanowear Inc.
NYHA Class III Heart Failure
Correlation of SOZO BIS Measures With CardioMEMS PA Pressure
This study aims to establish the degree to which change in the ratio of ECF to TBW measured using the SOZO BIS device correlates with change in end-expiratory end-diastolic PAP measured using the CardioMEMS HF System (St.
- Trial name
- NCT02939053
- Testing
- SOZO
- Where
- 2 sites in United States
- Volunteers
- 3 people
- Sponsor
- ImpediMed Limited